Low Brachial Artery Flow-Mediated Dilation Predicts Worse Prognosis in Hospitalized Patients with COVID-19

Background: Endothelial injury can be induced by coronavirus disease 2019 (COVID-19) and seems to exert a crucial pathogenic role in its most severe clinical manifestations. We aimed to investigate the association between brachial artery flow-mediated dilation (bFMD), a potential clinical and non-invasive measure of endothelial function, and in-hospital prognosis of COVID-19 patients. Methods: Brachial artery flow-mediated dilation was assessed in hospitalized COVID-19 patients within 48 h of hospital admission. The association between bFMD and either intensive care unit (ICU) admission or in-hospital death was explored using univariable and multivariable analyses. Results: Four hundred and eight patients were enrolled. Significantly lower bFMD values emerged in COVID-19 patients with either radiographic signs of pneumonia, respiratory distress, or the need for non-invasive ventilation compared with patients without these signs (p < 0.001, p = 0.001, and p < 0.001, respectively). Forty-two (10%) patients were admitted to the ICU, 76 (19%) patients died, and 118 (29%) patients met the composite endpoint of ICU admission/in-hospital death. At unadjusted Cox regression analysis showed that low bFMD (<4.4%, the median value) was associated with a higher risk for the composite endpoint of ICU admission/in-hospital death compared with high bFMD (≥4.4%, the median value) (HR 1.675, 95% CI 1.155–2.428, p = 0.007). Multi-adjusted Cox regression analyses showed that low bFMD was independently associated with a 1.519- to 1.658-fold increased risk for the composite endpoint of ICU admission/in-hospital death. Conclusions: Low bFMD predicts an unfavorable in-hospital prognosis in COVID-19 patients. The measurement of bFMD may be clinically useful in the prognostic stratification of COVID-19 patients upon hospital admission.

[1]  E. Ciolac,et al.  Determinants of endothelial dysfunction in noncritically ill hospitalized COVID‐19 patients: A cross‐sectional study , 2021, Obesity.

[2]  R. Arena,et al.  Endothelial function provides early prognostic information in patients with COVID-19: A cohort study , 2021, Respiratory Medicine.

[3]  F. Pène,et al.  Circulating Von Willebrand factor and high molecular weight multimers as markers of endothelial injury predict COVID-19 in-hospital mortality , 2021, Angiogenesis.

[4]  L. Wynants,et al.  Improving clinical management of COVID-19: the role of prediction models , 2021, The Lancet Respiratory Medicine.

[5]  T. Hobman,et al.  Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19 , 2020, Viruses.

[6]  D. Asch,et al.  Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic , 2020, JAMA internal medicine.

[7]  N. Le,et al.  SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress , 2020, Frontiers in Physiology.

[8]  H. Castro-Faria-Neto,et al.  Systemic microvascular endothelial dysfunction and disease severity in COVID-19 patients: Evaluation by laser Doppler perfusion monitoring and cytokine/chemokine analysis , 2020, Microvascular Research.

[9]  E. De Robertis,et al.  Role of endothelial dysfunction in the thrombotic complications of COVID-19 patients , 2020, Journal of Infection.

[10]  Stephen M. Ratchford,et al.  Vascular alterations among young adults with SARS-CoV-2 , 2020, American journal of physiology. Heart and circulatory physiology.

[11]  G. Reboldi,et al.  RAAS Inhibitors and Risk of Covid-19. , 2020, The New England journal of medicine.

[12]  Chuanmin Tao,et al.  An enlightening role for cytokine storm in coronavirus infection , 2020, Clinical Immunology.

[13]  F. Ruschitzka,et al.  Endothelial dysfunction in COVID-19: Current findings and therapeutic implications , 2020, Atherosclerosis.

[14]  M. Banach,et al.  Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone , 2020, Metabolism.

[15]  S. Jayasinghe,et al.  Non-invasive assessment of endothelial dysfunction: A novel method to predict severe COVID-19? , 2020, Medical Hypotheses.

[16]  M. Banach,et al.  Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19 , 2020, Angiology.

[17]  P. Libby,et al.  COVID-19 is, in the end, an endothelial disease , 2020, European heart journal.

[18]  L. Papazian,et al.  Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19 , 2020, The Journal of infectious diseases.

[19]  C. Weber,et al.  Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science , 2020, Cardiovascular research.

[20]  Jordan J. Clark,et al.  Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score , 2020, BMJ.

[21]  E. K. Ha,et al.  Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching , 2020, Gut.

[22]  F. Violi,et al.  Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? , 2020, Drugs.

[23]  Michael D Healy,et al.  SARS-CoV-2 viral load is associated with increased disease severity and mortality , 2020, Nature Communications.

[24]  L. Margolis,et al.  Dynamics of coagulopathy in patients with different COVID-19 severity , 2020, medRxiv.

[25]  C. D. Dela Cruz,et al.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.

[26]  D. Yellon,et al.  The cytokine storm of COVID-19: a spotlight on prevention and protection , 2020, Expert opinion on therapeutic targets.

[27]  A. Zangrillo,et al.  Decreased in-hospital mortality in patients with COVID-19 pneumonia , 2020, Pathogens and global health.

[28]  Deepak K Nandikanti,et al.  Medical Management of COVID-19: Evidence and Experience , 2020, Journal of clinical medicine research.

[29]  P. Carmeliet,et al.  COVID-19: the vasculature unleashed , 2020, Nature Reviews Immunology.

[30]  D. Kelvin,et al.  COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction , 2020, Cardiovascular research.

[31]  P. Salari,et al.  COVID-19 and off label use of drugs: an ethical viewpoint , 2020, DARU Journal of Pharmaceutical Sciences.

[32]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[33]  Dong Wei,et al.  Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score , 2019, Front. Microbiol..

[34]  C. Oury,et al.  A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril , 2019, Cardiology and therapy.

[35]  Tsung-Ming Lee,et al.  Blockade of Cardiac Proton Pump Impairs Ventricular Remodeling Through a Superoxide-DDAH-Dependent Pathway in Infarcted Rats. , 2019, Acta Cardiologica Sinica.

[36]  E. Mannarino,et al.  Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy , 2016, Scientific Reports.

[37]  W. Gasper,et al.  Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research. , 2014, Journal of visualized experiments : JoVE.

[38]  E. Mannarino,et al.  Age-Specific Relationship of Aortic Pulse Wave Velocity With Left Ventricular Geometry and Function in Hypertension , 2007, Hypertension.

[39]  T. Heeren,et al.  Endothelial function in HIV-infected persons. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  E. Mannarino,et al.  Acute inflammatory state during influenza infection and endothelial function. , 2005, Atherosclerosis.

[41]  E. Mannarino,et al.  Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. , 2005, Atherosclerosis.

[42]  A. Morelli,et al.  Nitric Oxide Regulates Immune Cell Bioenergetic: A Mechanism to Understand Immunomodulatory Functions of Nitric Oxide-Releasing Anti-Inflammatory Drugs , 2004, The Journal of Immunology.

[43]  P. Maes,et al.  Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound☆ , 2004, International Journal of Infectious Diseases.